Supreme Court: Uncrystallized Contractual Damages Not an Operational Debt under Section 9 IBC  ||  Supreme Court: Interest Accrued in Suspense Account After NPA Classification is Recoverable as Debt  ||  Supreme Court: S.69 GST Arrest Order with “Reasons to Believe” Must Precede Arrest  ||  Supreme Court: Winding-Up Proceedings Period Cannot be Excluded under Section 14 Limitation Act  ||  Supreme Court: Separate Appeals Unnecessary Against Common Judgment on Suit and Counterclaim  ||  Supreme Court: Unsuccessful Party Can Seek Post-Award Section 9 Relief in Exceptional Cases  ||  Delhi HC Rejects Black Money Act Challenge, Imposes Rs. 60,000 Costs over Prosecution Avoidance  ||  Delhi HC Affirms Teacher's POCSO Conviction, Urges Schools to Encourage Children to Speak Up  ||  Kerala HC: NGO Funding Peaceful Protests Can't Justify FCRA Renewal Denial  ||  Delhi HC: Courts Cannot Judge Sufficiency of Material For Issuing Look Out Circular    

National Pharmaceutical Pricing Authority Notifies All Medical Devices Under Price Control - (02 Apr 2020)

LAW OF MEDICINE

National Pharmaceutical Pricing Authority has notified all medical devices sold in India as ‘drugs’ to bring the devices — such as syringes, needles, cardiac stents, a knee implant, digital thermometers, CT scan, MRIs and dialysis machines — under the purview of price control and prohibit firms from hiking their costs by more than 10% annually at a time.

Tags : NATIONAL PHARMACEUTICAL PRICING AUTHORITY   ALL MEDICAL DEVICES UNDER PRICE CONTROL  

Share :        

Disclaimer | Copyright 2026 - All Rights Reserved